1 active not recruiting, 1 completed, 1 recruiting. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
Follow IBI302: new trials by email Literature Review of IBI302 trials Research Report on IBI302
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD IBI302 8mg dose - Neovascular Age-related Macular Degeneration | Phase 2 | Recruiting | Innovent Biologics Technology Limited (Shanghai R&D Center) | 800 | 2025-12-05 | 2026-01-08 |
| A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（DME） IBI302, Faricimab - Diabetic Macular Oedema | Phase 2 | Active not recruiting | Innovent Biologics Technology Limited (Shanghai R&D Center) | 150 | 2025-04-24 | 2026-05-27 |
| A Study of IBI302 in Patients With nAMD Low dose IBI302, High dose IBI302, Aflibercept - Neovascular Age-related Macular Degeneration | Phase 2 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 231 | 2021-04-28 | 2024-11-18 |
Innovent Biologics Technology Limited (Shanghai R&D Center) (2) · Innovent Biologics (Suzhou) Co. Ltd. (1)
China (3)